Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00230828
Status:
COMPLETED
Last Update Posted:
2013-09-12
First Post:
2005-09-12
Brief Title:
Patient-reported Outcomes in the Treatment of Schizophrenia
Sponsor:
Solvay Pharmaceuticals
Organization:
Solvay Pharmaceuticals
Study Overview
Official Title:
Patient-reported Outcomes With Bifeprunox or Olanzapine in the Treatment of Schizophrenia A Pharmacoeconomic Study Carried Out in Connection With the S1543003 And S1543004 Clinical Trials
Status:
COMPLETED
Status Verified Date:
2007-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None